Achieve Life Sciences, Inc. has announced a proposed underwritten public offering, according to a prospectus filed with the SEC. The company plans to offer and sell shares of its common stock, along with accompanying common warrants. Achieve intends to utilize the proceeds to advance cytisinicline, its treatment for nicotine dependence, through potential FDA approval and for general corporate purposes. Citizens Capital Markets and Raymond James are managing the offering, with Lake Street Capital Markets, LLC serving as a financial advisor. The offering's completion is contingent on market conditions, and final terms will be disclosed in a subsequent prospectus supplement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-091055), on June 27, 2025, and is solely responsible for the information contained therein.